Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CMKLR1 | Q99788 | 14/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180442 | 0.84 | CMKLR1 (0.38) | ESR1CMKLR1PDE4APDE4BPDE4C | |
| SCHEMBL6182817 | 0.83 | ESR1 (0.39) | ESR1CMKLR1PDE4APDE4BPDE4C | |
| SCHEMBL683162 | 0.81 | ESR1 (0.40) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31522514 | 0.81 | ESR1 (0.43) | ESR1CMKLR1 | |
| SCHEMBL3167730 | 0.81 | PDE4A (0.41) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3603291 | 0.81 | ESR1 (0.41) | ESR1CMKLR1PDE4APDE4BPDE4C | |
| SCHEMBL6185088 | 0.80 | ESR1 (0.42) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6796557 | 0.80 | PTGDR2 (0.47) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3176719 | 0.80 | TEAD1 (0.53) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3604069 | 0.80 | TEAD1 (0.43) | ESR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| CN-101166733-A | Pyrazole derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-5958953-A | Substituted indazole derivatives | PFIZER INC (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1223651-A | Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors | PFIZER (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1217714-A | Substituted indazole derivatives and their use as Phosphodiesterase (PDE) type IV and inhibitors of the production of Tumor Necrosis Factor (TNF) | PFIZER (US) | 1999-05-26 | — | — | CN | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999023076-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0912521-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912558-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0816357-A1 | Substituted indazole derivatives | PFIZER INC. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997049702-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS | PFIZER INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997042174-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | ESR1 4016/4885CMKLR1 4101/4885PDE4A 1/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | ESR1 4016/4885CMKLR1 4101/4885PDE4A 1/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | ESR1 4016/4885CMKLR1 4101/4885PDE4A 1/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | ESR1 4016/4885CMKLR1 4101/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.